Dose-related effects of propericiazine in rats

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 2, 2003, Pages 227-231

  Cechin, E M ^a   Quevedo, J ^b   Barichello, T ^b   Machado Vieira, R ^c,d   Gentil, V ^c   Kapczinski, F ^d  

^a Programa de Pós graduação em Envelhecimento Humano   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Anxiety; Diazepam; Elevated plus maze; Memory; Propericiazine

Indexed keywords

CHLORPROMAZINE; DIAZEPAM; DRUG VEHICLE; NEUROLEPTIC AGENT; PERICIAZINE; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PROPYLENE GLYCOL; SULPIRIDE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; HABITUATION; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; RAT; REVIEW; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0037291448     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000200010     Document Type: Review

References (15)

1. Ban OT (1969). Psychopharmacology. Williams & Wilkins, Baltimore, MD, USA.
2. Anonymous (1967). Pericyazine. British Medical Journal, 1: 352-353.
3. Wiecek Z (1971). Attempts at treatment of children at a special institution with propericiazine. Psychiatria Polska, 5: 61-63.
4. Litinschi G, Fechervary E & Ciumageanu D (1970). Some results of the use of propericiazine (RP8909) in the treatment of disorders of conduct and character in children and adolescents. Neurologia, Psihiatria, Neurochirurgia, 15: 493-504.
5. Takahashi M & Akagi M (1996). Case report of sodium valproate treatment of aggression associated with Alzheimer's disease. No To Shinkei. Brain and Nerve, 48: 757-760.
6. Nishikawa T, Tanaka M, Tsuda A, Koga I & Uchida Y (1989). Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine. Psychopharmacology, 82: 153-156.
7. Jenner FA (1970). Pericyazine in clinical practice. Laval Medical, 41: 796-804.
8. 3-receptor agonist 7-OH-DPAT. Pharmacology, Biochemistry and Behavior, 54: 79-84.
9. Tischler B, Patriasz K, Beresford J & Bunting R (1972). Experience with pericyazine in profoundly and severely retarded children. Canadian Medical Association Journal, 106: 136-141.
10. Rickels K & Schweizer EE (1987). Current pharmacotherapy in anxiety and panic. In: Meltzer HY (Editor), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, NY, USA, 1193-1203.
11. Pellow S, Chopin P, File SE & Briley M (1985). Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14: 149-176.
12. Salgueiro JB, Ardenghi P, Dias M, Ferreira MBC, Izquierdo I & Medina JH (1997). Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacology, Biochemistry and Behavior, 58: 1-5.
13. Quevedo J, Vianna MRM, Roesler R, De-Paris F, Izquierdo I & Rose SPR (1999). Two time windows of anisomycin-induced amnesia for inhibitory avoidance training in rats: protection from amnesia by pretraining but not preexposure to the task apparatus. Learning and Memory, 6: 600-607.
14. Coward DM (1982). Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in rat. Psychopharmacology, 78: 180-184.
15. Marco E, Mao CC, Revueleta A, Peralta E & Costa E (1978). Turnover rates of gamma-aminobutyric acid in substantia nigra, N. caudatus, globus pallidus and N. accumbens of rats injected with cataleptogenic and non-cataleptogenic antipsychotics. Neuropharmacology, 17: 589-596.